Published in Pharmacoepidemiol Drug Saf on April 01, 2012
Diabetes and depression? Secular trends in the use of antidepressants among persons with diabetes in Finland in 1997-2007. Pharmacoepidemiol Drug Saf (2010) 2.12
Economic effects of clinical pharmacy interventions: a literature review. Am J Health Syst Pharm (2008) 3.11
Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis (2012) 2.00
A comparative study of European rare disease and orphan drug markets. Health Policy (2010) 1.73
Impact, regulation and health policy implications of physician migration in OECD countries. Hum Resour Health (2004) 1.72
Budget impact analysis of orphan drugs in Belgium: estimates from 2008 to 2013. J Med Econ (2010) 1.59
Generic and therapeutic substitution: ethics meets health economics. Int J Clin Pharm (2011) 1.45
Increasing nurse staffing levels in Belgian cardiac surgery centres: a cost-effective patient safety intervention? J Adv Nurs (2010) 1.42
Generic medicine pricing in Europe: current issues and future perspective. J Med Econ (2008) 1.32
Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy (2011) 1.29
International trends in lifelong learning for pharmacists. Am J Pharm Educ (2007) 1.27
A comparative analysis of remuneration models for pharmaceutical professional services. Health Policy (2009) 1.18
Drugs for rare diseases: influence of orphan designation status on price. Appl Health Econ Health Policy (2011) 1.10
The costs of breast cancer prior to and following diagnosis. Eur J Health Econ (2010) 1.09
Critical assessment of belgian reimbursement dossiers of orphan drugs. Pharmacoeconomics (2011) 1.09
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis (2013) 1.08
Personalizing health care: feasibility and future implications. BMC Med (2013) 1.07
Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy (2013) 1.00
Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res (2013) 0.97
The impact of reference-pricing systems in Europe: a literature review and case studies. Expert Rev Pharmacoecon Outcomes Res (2011) 0.97
Does the market share of generic medicines influence the price level?: a European analysis. Pharmacoeconomics (2011) 0.96
Shining a light in the black box of orphan drug pricing. Orphanet J Rare Dis (2014) 0.96
Dabigatran - a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Front Pharmacol (2013) 0.95
Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy (2010) 0.94
The impact of informing psychiatric patients about their medication: a systematic review. Pharm World Sci (2007) 0.94
Opposing expectations and suboptimal use of a local antibiotic hospital guideline: a qualitative study. J Antimicrob Chemother (2008) 0.93
Drug shortages in European countries: a trade-off between market attractiveness and cost containment? BMC Health Serv Res (2014) 0.93
Clinical evidence for orphan medicinal products-a cause for concern? Orphanet J Rare Dis (2013) 0.90
How can pharmacist remuneration systems in Europe contribute to generic medicine dispensing? Pharm Pract (Granada) (2012) 0.90
Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial. Crit Care (2012) 0.89
Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics (2014) 0.88
Economic evaluations of homeopathy: a review. Eur J Health Econ (2013) 0.87
European drug shortages: a call for action! Int J Pharm Pract (2013) 0.87
Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res (2014) 0.87
Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy (2013) 0.87
Kiovig for primary immunodeficiency: reduced infusion and decreased costs per infusion. Int Immunopharmacol (2011) 0.86
Reimbursement of orphan drugs in Belgium: what (else) matters? Orphanet J Rare Dis (2014) 0.86
Length of stay after reaching clinical stability drives hospital costs associated with adult community-acquired pneumonia. Scand J Infect Dis (2012) 0.86
Market access of cancer drugs in European countries: improving resource allocation. Target Oncol (2013) 0.85
Generic atypical antipsychotic drugs in Belgium: their influence and implications. J Comp Eff Res (2013) 0.84
Evaluating and improving orphan drug regulations in Europe: a Delphi policy study. Health Policy (2012) 0.84
Can authorities appreciably enhance the prescribing of oral generic risperidone to conserve resources? Findings from across Europe and their implications. BMC Med (2014) 0.83
Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics (2013) 0.82
[Orphan diseases and orphan medicines: a Belgian and European study]. J Pharm Belg (2009) 0.82
Valorising and creating access to innovative medicines in the European union. Front Pharmacol (2011) 0.81
Body composition, volumetric and areal bone parameters in male-to-female transsexual persons. Bone (2008) 0.79
Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharmacoecon Outcomes Res (2015) 0.79
Continuous versus on-demand pharmacotherapy of allergic rhinitis: evidence and practice. Respir Med (2010) 0.78
Implementing a hospital guideline on pneumonia: a semi-quantitative review. Int J Qual Health Care (2007) 0.77
Analysis of Spanish generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res (2014) 0.77
Development and validation of COMPASS: clinical evidence of orphan medicinal products - an assessment tool. Orphanet J Rare Dis (2013) 0.77
A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium. Curr Med Res Opin (2008) 0.77
Stimulating pharmaceutical innovation in the EU. Expert Rev Pharmacoecon Outcomes Res (2011) 0.76
The economic burden of COPD exacerbations. COPD (2010) 0.76
Comparative effectiveness research and measuring the level of pharmaceutical innovation in the EU. J Comp Eff Res (2012) 0.76
Does increased use of generic medicines by elders in Belgium help to contain escalating health care budgets? J Aging Soc Policy (2014) 0.75
Prescription of antibiotics in hospitals: prescribers' opinions matter. Lancet Infect Dis (2011) 0.75
Information on antidepressants for psychiatric inpatients: the divide between patient needs and professional practice. Pharm Pract (Granada) (2013) 0.75
Comment: economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder. Ann Pharmacother (2011) 0.75
Hurdles that impede economic evaluations of welfare interventions. Expert Rev Pharmacoecon Outcomes Res (2015) 0.75
Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation. J Antimicrob Chemother (2011) 0.75
Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium. Expert Rev Pharmacoecon Outcomes Res (2013) 0.75
Estimation and comparison of ostomy appliance costs with tariffs in Belgium. Eur J Health Econ (2006) 0.75
Informing your patients about their medicines: a daily challenge. Int J Pharm Pract (2011) 0.75
Analysis of French generic medicines retail market: why the use of generic medicines is limited. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
Atherosclerotic cardiovascular diseases in Belgium: a cost-of-illness analysis. Cardiovasc Drugs Ther (2008) 0.75
Use and costs of anti-secretory and cardiovascular co-medication in osteoarthritis patients treated with selective or non-selective NSAIDS. Pharm World Sci (2006) 0.75
Cardiovascular drug use prior to diagnosis of diabetes: a pilot study in community pharmacy. Int J Pharm Pract (2009) 0.75
International comparison of orthotic brace prices. Eur J Health Econ (2008) 0.75
Analysis of the Italian generic medicines retail market: recommendations to enhance long-term sustainability. Expert Rev Pharmacoecon Outcomes Res (2014) 0.75
Reforming the Belgian market for orthotic braces: what can we learn from the international experience? Health Policy (2008) 0.75
Making patient safety a priority: community pharmacy and tools to assure drug supply. Int J Pharm Pract (2010) 0.75
Hospital pharmacists versus hospital administrators: a struggle for clinical pharmacy services. Expert Rev Pharmacoecon Outcomes Res (2009) 0.75
Differentiated information on antidepressants at hospital discharge: a hypothesis-generating study. Int J Pharm Pract (2012) 0.75
Do tariffs and prices correspond with costs? A case study of orthotic braces. J Med Econ (2008) 0.75
Discharge management for patients in Flemish psychiatric hospitals. J Eval Clin Pract (2010) 0.75